Author/Editor		Katičić, Miroslava; Duvnjak, Marko; Vucelić, Boris; Križman, Igor; Pavić-Sladoljev, Dubravka; Čulig, Josip
Title		Ranitidine bismuth citrate and azithromycin with or without amoxicillin in the eradication of Helicobacter pylori in peptic ulcer patients
Type		članek
Source		Pharmaca
Vol. and No.		Letnik 38
Publication year		2000
Volume		str. 147-55
Language		eng
Abstract		Background: Infection with H. pylori leads to a disease spectrum ranging from non-ulcer dyspepsia to peptic ulceration and gastric adenocarcinoma. There is a definite link between duodenal ulcer and H. pylori infection, as seen by the fact that 95% of patients with duodenal ulcer are found to be infected with the organism, as well as by a decreased disease recurrence when the organism is eradicated. H. pylori is found in 80% of patients with gastric ulcer and in 70% of patients with gastric carcinomas. Chronic H. pylori infection will eventually result in active gastritis. This does not cause symptoms in a majority of patients, although it may have a causal role in non-ulcer dyspepsia. Peptic ulcer can be cured by eradicating H. pylori. One-week proton pump inhibitorbased triple therapy with two antibiotics (amoxicillin, nitroimidazoles, macrolides) has been considered by Maastricht consensus guidelines as optimal therapy (eradication rate over 80% on an intention-to-treat/11T analysis with relatively few side effects). At the same time, ranitidine bismuth ciirate (RBC), a novel compound with the cationic salt of ranitidine combined with anionic bismuth citrate, has been introduced for the treafment of peptic ulcer and H. pylori infection. Therefore we decided to conduct a study to assess the efficacy and safety of short-term dual therapy with RBC and azithromycin in comparison with triple therapy with RBC, azithromycin and amoxicillin. (Abstract truncated at 2000 characters)
Descriptors		PEPTIC ULCER HELICOBACTER PYLORI RANITIDINE AZITHROMYCIN AMOXICILLIN DRUG THERAPY, COMBINATION TREATMENT OUTCOME